体内
甲型流感病毒
病毒
病毒学
转录组
离体
生物
炎症
化学
免疫系统
体外
病毒复制
肺
免疫学
药品
下调和上调
泛素
单克隆抗体
CTL公司*
蛋白质组
病毒包膜
微生物学
细胞
抗药性
细胞培养
作者
Yuan Li,Haotong Wang,Daxin Yang,Simin Yang,Xiajin Li,Shuangdi Duan,Zhaohong Mo,金波,金波,Wenyi Huang,Jingkang Tan,Yuyan Chen,Zhuo Luo
标识
DOI:10.1016/j.phrs.2026.109773
摘要
Influenza virus remained a persistent global public-health threat. Current anti-influenza therapeutics were hampered by drug resistance and narrow therapeutic windows, creating an urgent need for innovative antiviral strategies. By screening a medicine-food homology herbal library, we identified Mogroside V (MV), a well-known natural tetracyclic triterpene glycoside monomer derived from Siraitia grosvenorii, as a potent inhibitor against influenza, including oseltamivir-resistant strains. MV showed negligible cytotoxicity, while reducing viral loads, mitigating pulmonary inflammation and lung injury. Thermal proteome profiling and molecular assays confirmed CNOT1 as the direct host target of MV. Public transcriptomic analyses suggested that CNOT1 is associated with influenza infection in patient-derived blood datasets and is enriched in specific lung cell populations in an ex vivo respiratory virus infection model. Gain- and loss-of-function assays plus transmission electron microscopy verified that CNOT1 promotes viral budding. Mechanistically, CNOT1 binds viral M2 and shields it from MARCH8-dependent ubiquitination-mediated degradation. MV disrupted CNOT1-M2 interaction to abolish M2 stabilization and induce budding defects. Our work defines a new CNOT1-MARCH8-M2 axis controlling influenza propagation and supports MV as a promising anti-influenza therapeutic candidate.
科研通智能强力驱动
Strongly Powered by AbleSci AI